Advertisement

Medical Oncology

, Volume 23, Issue 4, pp 507–513 | Cite as

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

  • Sujith Kalmadi
  • Giles McNeill
  • Mellar Davis
  • David Peereboom
  • David Adelstein
  • Tarek Mekhail
Original Article

Abstract

Background

A platinum doublet has been the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) and good performance status. This treatment results in almost a doubling of 1-yr survival, along with an improvement in quality of life despite treatment-related toxicities. However, platinum-based treatment may be associated with significant toxicity.

Materials and Methods

In this trial, we prospectively evaluated a weekly regimen of docetaxel and gemcitabine for advanced NSCLC. The endpoints of this study included objective response rate, survival, and toxicity. Forty-two patients with previously untreated, advanced NSCLC with PS 0-1 were included. Patients received docetaxel (36 mg/m2) and gemcitabine (600 mg/m2) on d 1, 8, and 15 of a 28-d cycle. Responses were assessed every two cycles. The median age was 63 yr; with 22 males and 20 females; 67% were ≥60 years old; and 38 patients had stage IV disease.

Results

In the intent-to-treat (ITT) analysis of response, 16 patients had a partial response (38%) and 15 patients had stable disease (36%). The 1-yr survival was 48%; median survival for all patients was 11.3 mo and the median progression-free survival was 5.1 mo. Toxicities (≥grade 3) included neutropenia (29%), asthenia (26%), diarrhea (14%), thrombocytopenia (10%), pneumonitis (7%), peripheral neuropathy (5%), peripheral edema (5%), nail changes (2%), and myositis (2%).

Conclusions

This study demonstrated that this non-platinum doublet (docetaxel+gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens.

Key Words

Docetaxel gemcitabine chemotherapy advanced non-small cell lung cancer phase II 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11(10):1866–1872.PubMedGoogle Scholar
  3. 3.
    Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer Results of a meta-analysis of the literature. Chest 1994;106(3):861–865.PubMedGoogle Scholar
  4. 4.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000(2):CD002139.Google Scholar
  5. 5.
    Souquet PJ, Chauvin F, Boissel JP, Bernard JP. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 1995;12(Suppl 1):S147–154.CrossRefGoogle Scholar
  6. 6.
    Vansteenkiste JF, et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12(9): 1221–1230.PubMedCrossRefGoogle Scholar
  7. 7.
    Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10): 2095–2103.PubMedGoogle Scholar
  8. 8.
    Lynch TJ, Jr. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non—small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):5–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Roszkowski K, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27(3):145–157.PubMedCrossRefGoogle Scholar
  10. 10.
    Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354–2362.PubMedGoogle Scholar
  11. 11.
    Hainsworth JD, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19(15):3500–3505.PubMedGoogle Scholar
  12. 12.
    Lilenbaum RC, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001;92(8):2158–2163.PubMedCrossRefGoogle Scholar
  13. 13.
    Petrioli R, et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 2003;39(1):85–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsunoda T, et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2004;54(2):173–177.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohe Y, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15(1):45–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Mekhail T, et al. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer 2003;97(1):170–178.PubMedCrossRefGoogle Scholar
  17. 17.
    Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999;10(8):943–947.PubMedCrossRefGoogle Scholar
  18. 18.
    WHO handbook for reporting results of cancer treatment. Geneva (Switzerland) 1979.Google Scholar
  19. 19.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958(53):457–481.CrossRefGoogle Scholar
  20. 20.
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899–909.Google Scholar
  21. 21.
    Georgoulias V, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001;357(9267): 1478–1484.PubMedCrossRefGoogle Scholar
  22. 22.
    Kosmidis P., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20(17): 3578–3585.PubMedCrossRefGoogle Scholar
  23. 23.
    Van Meerbeeck JP, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced NSCLC. In: ASCO 2001.Google Scholar
  24. 24.
    Pfister DG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin. Oncol 2004;22(2):330–353.PubMedCrossRefGoogle Scholar
  25. 25.
    Rizvi NA, et al. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol 1999;26(5 Suppl 16):27–31; discussion 41–42.PubMedGoogle Scholar
  26. 26.
    Rizvi NA. Docetaxel (Taxotere) and gemcitabine in combination therapy. Semin Oncol 1999;26(3 Suppl 11):19–22.PubMedGoogle Scholar
  27. 27.
    Neubauer MA, et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 2005;47(1):121–127.PubMedCrossRefGoogle Scholar
  28. 28.
    Spiridonidis CH, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 2001;12(1):89–94.PubMedCrossRefGoogle Scholar
  29. 29.
    van Oosterom AT. Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. Semin Oncol 1999;26(3 Suppl 10):8–11.PubMedGoogle Scholar
  30. 30.
    J. R. Rigas MC, B. Cole, A. Evans, R. Page, F. Yunus, M. Ruben, H. Ghazal, K. Dragnev. The Dartmouth Non-Platinum Based Chemotherapy Trial Investigators; Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH. Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112). In: 2004 ASCO annual meeting 2004.Google Scholar
  31. 31.
    Hainsworth JD, Burris HA, 3rd, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):21–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Kakolyris S, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001;32(2):179–187.PubMedCrossRefGoogle Scholar
  33. 33.
    Hejna M, et al. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 2000;89(3):516–522.PubMedCrossRefGoogle Scholar
  34. 34.
    Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–98.PubMedCrossRefGoogle Scholar
  35. 35.
    Rosell Rea. ERCC1 mRNA based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer. In: ASCO 40th annual meeting 2005.Google Scholar
  36. 36.
    Sandler Aea. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599. In: ASCO annual meeting: 2005; 2005.Google Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Sujith Kalmadi
    • 1
  • Giles McNeill
    • 1
  • Mellar Davis
    • 1
  • David Peereboom
    • 1
  • David Adelstein
    • 1
  • Tarek Mekhail
    • 1
  1. 1.Thoracic and Gastrointestinal oncology, Taussig Cancer CenterCleveland ClinicClevelandUSA

Personalised recommendations